Archive


Category: Checkpoint Therapeutics

  • Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab

    Waltham, Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:  CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced  positive topline results from its registration-enabling clinical trial evaluating the safety and  efficacy of its anti-PD-L1 antibody, cosibelimab, administered as a fixed dose of 800 mg every  two weeks in patients with metastatic cutaneous squamous cell carcinoma (“cSCC”).   The […]